12 May 2026 : Original article
A Retrospective Study of 518 Kidney Transplant Recipients to Evaluate the Association of Antiplatelet Therapy With Long-Term Cardiovascular Events and All-Cause Mortality
Gavin Christy BCEF 1, Andres Mata ABE 2, Zalan Shah B 1, Ananta M.H. Sriram B 1, Diana Pfeiffer B 1, Taylor R. Coffman
B 1, Madeline K. Johnson E 1, Sahita Gandra E 1, Krista L. Lentine ADEG 3, Mina M. Benjamin ADE 4*
DOI: 10.12659/AOT.951325
Ann Transplant 2026; 31:e951325
Table 6 Adjusted Cox proportional hazards model for the composite endpoint of all-cause mortality and major adverse cardiovascular events in 518 kidney transplant recipients. The primary prevention subgroup included 368 patients without known cardiovascular disease.
| Variable | Study group | Primary prevention subgroup | ||||
|---|---|---|---|---|---|---|
| Hazard ratio | 95% confidence interval | P value | Hazard ratio | 95% confidence interval | P value | |
| Age | 1.03 | 1.01–1.04 | 1.02 | 1.01–1.04 | ||
| Antiplatelet therapy | 0.67 | 0.45–0.99 | 0.79 | 0.44–1.44 | 0.45 | |
| Hemodialysis | 1.61 | 1.01–2.34 | 1.52 | 0.91–2.54 | 0.11 | |
| Coronary artery disease | 1.51 | 1.00–2.29 | – | – | – | |
| Diabetes mellitus | 1.64 | 1.09–2.46 | – | – | – | |
| Myocardial infarction | 1.04 | 0.51–2.15 | 0.91 | – | – | – |